Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 9/20 | 0.62 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.60 |
| ▸ | CIB1 | Q99828 | 4/20 | 0.56 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.50 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19345180 | 0.99 | CD274 (0.61) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL21548543 | 0.99 | CD274 (0.61) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19754485 | 0.98 | CD274 (0.63) | CD274PDCD1CIB1KLKB1KLK5 | |
| SCHEMBL19345474 | 0.98 | CD274 (0.63) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19345140 | 0.98 | CD274 (0.63) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19345169 | 0.98 | CD274 (0.62) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19345204 | 0.98 | CD274 (0.63) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19345165 | 0.98 | CD274 (0.63) | CD274PDCD1CIB1KLKB1CTSG | |
| SCHEMBL19345257 | 0.98 | CD274 (0.64) | CD274PDCD1CIB1KLKB1EPHA2 | |
| SCHEMBL19345630 | 0.98 | CD274 (0.61) | CD274PDCD1CIB1KLKB1CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191113-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20170260237-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260237-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | CD274 1/4885PDCD1 2/4885CIB1 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.